humoral immune responsiveness
Recently Published Documents

TOTAL DOCUMENTS

18
(FIVE YEARS 0)

H-INDEX

12
(FIVE YEARS 0)
Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab

2008 ◽  
Vol 46 (1) ◽  
pp. 8-15 ◽  
Author(s):  
Christoph Kessel ◽  
Christoph Königs ◽  
Richard Linde ◽  
Carmen Escuriola-Ettinghausen ◽  
Hildegard Stoll ◽  
...  
Keyword(s):  
Factor Viii ◽  
B Cell ◽  
Immune Responsiveness ◽  
Humoral Immune ◽  
Cell Ablation ◽  
Before And After ◽  
Humoral Immune Responsiveness

scholarly journals Rituximab treatment results in impaired secondary humoral immune responsiveness

Blood ◽  
2002 ◽  
Vol 100 (6) ◽  
pp. 2257-2259 ◽  
Author(s):  
Lizet E. van der Kolk ◽  
Joke W. Baars ◽  
Martin H. Prins ◽  
Marinus H. J. van Oers
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Infectious Complications ◽  
Low Grade ◽  
Immune Responsiveness ◽  
B Cell Depletion ◽  
Treatment Results ◽  
Humoral Immune ◽  
Immunoglobulin Levels ◽  
Humoral Immune Responsiveness

Abstract In lymphoma patients, treatment with chimeric CD20 monoclonal antibodies (rituximab) results in a depletion of normal and malignant B cells, persisting for 6 to 9 months. This B-cell depletion leads neither to a decrease in immunoglobulin levels nor an increase in the number of infectious complications. However, the effect of rituximab treatment on the immune responsiveness is unknown. In 11 patients with relapsed, low-grade lymphoma, we investigated the effect of rituximab treatment on the humoral immune response to 2 primary antigens and 2 recall antigens. After rituximab treatment, the humoral immune response to the recall antigens was significantly decreased when compared with the response before treatment. Already before rituximab treatment, none of these patients was able to mount a response to the primary antigens. These findings are relevant regarding the feasibility of rituximab in maintenance treatment and may also offer a rationale for the treatment of antibody-mediated autoimmune diseases with rituximab.

scholarly journals Rituximab treatment results in impaired secondary humoral immune responsiveness

Blood ◽  
2002 ◽  
Vol 100 (6) ◽  
pp. 2257-2259 ◽  
Author(s):  
Lizet E. van der Kolk ◽  
Joke W. Baars ◽  
Martin H. Prins ◽  
Marinus H. J. van Oers
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Infectious Complications ◽  
Low Grade ◽  
Immune Responsiveness ◽  
B Cell Depletion ◽  
Treatment Results ◽  
Humoral Immune ◽  
Immunoglobulin Levels ◽  
Humoral Immune Responsiveness

In lymphoma patients, treatment with chimeric CD20 monoclonal antibodies (rituximab) results in a depletion of normal and malignant B cells, persisting for 6 to 9 months. This B-cell depletion leads neither to a decrease in immunoglobulin levels nor an increase in the number of infectious complications. However, the effect of rituximab treatment on the immune responsiveness is unknown. In 11 patients with relapsed, low-grade lymphoma, we investigated the effect of rituximab treatment on the humoral immune response to 2 primary antigens and 2 recall antigens. After rituximab treatment, the humoral immune response to the recall antigens was significantly decreased when compared with the response before treatment. Already before rituximab treatment, none of these patients was able to mount a response to the primary antigens. These findings are relevant regarding the feasibility of rituximab in maintenance treatment and may also offer a rationale for the treatment of antibody-mediated autoimmune diseases with rituximab.

Load More ...
Sign in / Sign up

Export Citation Format

Share Document